Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling DOI Open Access
Carlos Daviña‐Núñez, Sonia Pérez‐Castro, Jorge Julio Cabrera

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2948 - 2948

Published: March 24, 2025

The current clinical management of SARS-CoV-2 disease control and immunity may be not optimal anymore. Reverse transcription polymerase chain reaction (RT-PCR) genomic viral RNA is broadly used for diagnosis, even though the virus still detectable when it already non-infectious. Regarding serology, commercial assays mostly rely on ancestral spike detection despite significant changes in genetic sequence circulating variants. We followed a group 105 non-vaccinated individuals, measuring their shedding until negativity antibody response up to six months. mean period negative RT-PCR result was 2.2 weeks using subgenomic RNA-E as target, 5.2 target. Our neutralising results suggest that, challenged against variant different from first exposure, immunoassays are suboptimal at predicting capacity sera. Additionally, anti-Alpha anti-Delta antibodies showed very low cross-reactivity between This study provides insights into immune pre-Omicron variants like Alpha Delta, which have been understudied published literature. These conclusions point potential improvements cases order organise vaccination campaigns select monoclonal treatments.

Language: Английский

Neutralizing and binding antibody dynamics following primary and booster COVID-19 vaccination among healthcare workers DOI Creative Commons
Irmak Güzel, Gamze ÖZTÜRK, Özgür Appak

et al.

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 14, 2025

Abstract Background Vaccine-induced neutralizing antibodies (NAbs) are key for COVID-19 protective-immunity. As the efficacy of SARS-CoV-2 vaccines declines over time and variants virus continue to emerge, need booster doses vaccine remains on agenda. The aim this study was assess NAbs dynamics its correlation with anti-RBD IgG levels during nine-month follow-up period after primary-CoronaVac vaccination vaccinations evaluate strategies. Methods This prospective longitudinal observational followed 226 healthcare workers who received primary (two CoronaVac) (CoronaVac or BNT162b2) immunization. Serum samples were collected at four different points, two booster. Anti-RBD antibody assessed SARS CoV-2 IgG-II-QUANT kit (Abbott, USA) determined ACE2-RBD-Neutralization-Assay (Dia-Pro, Italy) using a surrogate neutralization method. Factors affecting response analyzed. Statistical analysis performed IBM-SPSS-22.0. Results One month second dose CoronaVac, 79.2% participants had NAb, but decreased 49.7% by fourth influenced smoking, BMI chronic diseases. Boosters, regardless type, significantly raised NAb levels. Heterologous yielded higher responses. Both single double-BNT162b2 boosters resulted in similar There strong between following CoronaVac vaccination, leading identification predictive threshold presence NAb. type strength threshold-value. Conclusions rapidly vaccination. Boosters increased while heterologous combination induced greater response. able predict response, however varied since

Language: Английский

Citations

0
Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling DOI Open Access
Carlos Daviña‐Núñez, Sonia Pérez‐Castro, Jorge Julio Cabrera

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2948 - 2948

Published: March 24, 2025

The current clinical management of SARS-CoV-2 disease control and immunity may be not optimal anymore. Reverse transcription polymerase chain reaction (RT-PCR) genomic viral RNA is broadly used for diagnosis, even though the virus still detectable when it already non-infectious. Regarding serology, commercial assays mostly rely on ancestral spike detection despite significant changes in genetic sequence circulating variants. We followed a group 105 non-vaccinated individuals, measuring their shedding until negativity antibody response up to six months. mean period negative RT-PCR result was 2.2 weeks using subgenomic RNA-E as target, 5.2 target. Our neutralising results suggest that, challenged against variant different from first exposure, immunoassays are suboptimal at predicting capacity sera. Additionally, anti-Alpha anti-Delta antibodies showed very low cross-reactivity between This study provides insights into immune pre-Omicron variants like Alpha Delta, which have been understudied published literature. These conclusions point potential improvements cases order organise vaccination campaigns select monoclonal treatments.

Language: Английский

Citations

0